Nicotinamide - Biologic actions of an emerging cosmetic ingredient

International Journal of Cosmetic Science

Volumn 27, Issue 5, 2005, Pages 255-261

  Otte, N ^a   Borelli, C ^a   Korting, H C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Acne; Ceramide synthesis; Coenzyme NAD; Coenzyme NADP; Inflammation; PARP inhibition; Skin disease

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CERAMIDE; CHOLESTEROL; CLINDAMYCIN; CYTOCHROME P450; FATTY ACID; GLUCOSYLCERAMIDE; HISTAMINE; HISTAMINE RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 5; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PAPULEX; PHOSPHODIESTERASE; PROSTAGLANDIN E2; PROTEIN KINASE C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SPHINGOMYELIN; SPHINGOSINE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ACNE; ACNE VULGARIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATOPIC DERMATITIS; BURN; CARCINOGENESIS; CHOLESTEROL SYNTHESIS; CONTACT DERMATITIS; CUTANEOUS PARAMETERS; DERMATOHELIOSIS; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INHIBITION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STABILITY; DRUG TOLERABILITY; ENZYME INHIBITION; FLATULENCE; HEADACHE; HUMAN; HYPERPIGMENTATION; IMMUNOMODULATION; LIVER CLEARANCE; NAUSEA; OPIATE ADDICTION; OXIDATION REDUCTION REACTION; PELLAGRA; PEMPHIGOID; PHOTODERMATOSIS; PSORIASIS VULGARIS; REVIEW; ROSACEA; SCHIZOPHRENIA; SKIN DISEASE; SKIN IRRITATION; STROKE; TREATMENT OUTCOME; VOMITING; WITHDRAWAL SYNDROME;

EID: 25444492336     PISSN: 01425463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1467-2494.2005.00266.x     Document Type: Review

References (25)

1. Matts, P.J., Oblong, J.E. and Bissett, D.L. A review of the range of effects of niacinamide in human skin. IFSCC Mag. 5, 285-289 (2002).
2. Berger, F., Ramirez-Hernandez, M.H. and Ziegler, M. The new life of a centenarian: signalling functions of NAD(P). Trends Biochem. Sci. 29, 3 (2004).
3. Karthukeyan, K. and Thappa, D.M. Pellagra and skin. Int. J. Dermatol. 41, 476-481 (2002).
4. Namazi, M.R. Nicotinamide: a potential addition to the anti-psoriatic weaponry. FASEB J. 17, 1377-1379 (2003).
5. Hakozaki, T., Minwalla, L. and Zhuang, J. The effect of Nicotinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br. J. Dermatol. 147, 20-31 (2002).
6. Ungerstedt, J.S., Blombäck, M. and Söderström, T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin. Exp. Immunol. 131, 48-52 (2003).
7. Shalita, A.R., Smith, J.G. and Parish, L.C. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int. J. Dermatol. 34, 434-437 (1995).
8. Namazi, M.R. Nicotinamide-containing sunscreens for use in Australasian countries and cancer-provoking conditions. Med. Hypotheses 60, 544-545 (2003).
9. Bissett, D. Topical niacinamide and barrier enhancement. Cutis 70, 8-12 (2002).
10. Tronov, V.A., Konstantinov, E.M. and Petrakou, E. Nicotinamide "protects" resting lymphocytes exposed to hydrogen peroxide from necrosis but not from apoptosis. Cell. Biol. Toxicol. 18, 359-367 (2002).
11. Gaudineau, C. and Auclair, K. Inhibition of human P450 enzymes by nicotinic acid and nicotinamide. Biochem. Biophys. Res. Commun. 317, 950-956 (2004).
12. Getoff, N. Effect of vitamin C, E-acetate and betacarotene on the cytostatic activity of nicotinamide (Vitamin B3). In Vivo 17, 169-172 (2003).
13. Wozniacka, A., Sysa-Jedrzejowska, A. and Adamus, J. Topical application of NADH for the treatment of rosacea and contact dermatitis. Clin. Exp. Dermatol. 28, 61-63 (2003).
14. Namazi, M.R. Nicotinamide as a potential addition to the anti-atopic dermatitis armamentarium. Int. Immunopharmacol. 4, 709-712 (2003).
15. Tanno, O., Ota, Y. and Kitamura, N. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br. J. Dermatol. 143, 524-531 (2000).
16. Gensler, H.L. Prevention of photoimmunsuppression and photocarcinogenesis by topical nicotinamide. Nutr. Cancer 29, 157-162 (1997).
17. Shen, S.C., Yoshii, T. and Chen, Y.C. Nicotinamide reduces DNA damage caused by reactive oxygen species. 60th Annual Meeting. American Academy of Dermatology, New Orleans (2002).
18. Bisset, D.L., Miyamoto, K. and Sun, P. Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmentated spots in aging facial skin. Int. J. Cosmet. Sci. 26, 231-238 (2004).
19. Anonymous. Niacinamide. Altern. Med. Rev. 7, 525-529 (2002).
20. Fiveson, D.P., Brakeman, D.L. and Rosen, G.B. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch. Dermatol. 130, 753-758 (1994).
21. Berk, M.A. and Lorincz, A.L. The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report. Arch. Dermatol. 122, 670-674 (1986).
22. Tutrone, W.D., Spann, C.T. and Scheinfeld, N. Polymorphic light eruption. Dermatol. Ther. 16, 28-39 (2003).
23. Yang, J., Klaidman, L.K. and Chang, M.L. Nicotinamide therapy protects against both necrosis and apoptosis in a stroke model. Pharmacol. Biochem. Behav. 73, 901-910 (2002).
24. Anonymous. Nicotinamide: a potential anti-addiction weapon. Med. Hypotheses 62, 844-845 (2004).
25. Kaanders, J.H., Bussink, J. and von der Kogel, A.J. ACRON: a novel biology-based approach in radiotherapy. Lancet Oncol 3, 728-737 (2002).